Literature DB >> 3280868

[Hematologic or hemostaseologic "paraneoplastic syndromes" as prognostic factors?].

W Schneider1.   

Abstract

Paraneoplastic syndromes are early but seldom appearing remote effects of tumors. In contrast, hematological or hemostaseological tumor signs can be demonstrated nearly in every tumor patient, mostly, however, after prolonged disease. The signs result from interaction between tumor and host, they depend upon the monocyte-macrophage system and are mediated by interleukin-1. Therefore, strictly speaking, they are no paraneoplasias. By genetic instability and increasing heterogeneity, the tumor cell gradually overcomes this defence line and the clinical pictures of different metastatic diseases equalize slowly. Finally, main causes of death are equally occurring infectious and hemostaseological complications. They demonstrate the final breakdown of this defence system.

Entities:  

Mesh:

Year:  1988        PMID: 3280868     DOI: 10.1007/bf01774223

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  30 in total

Review 1.  Platelet-derived growth factor.

Authors:  C H Heldin; A Wasteson; B Westermark
Journal:  Mol Cell Endocrinol       Date:  1985-03       Impact factor: 4.102

Review 2.  Clinicopathologic features of thrombotic thrombocytopenic purpura.

Authors:  H C Kwaan
Journal:  Semin Hematol       Date:  1987-04       Impact factor: 3.851

Review 3.  Clinical implications of tumor-cell heterogeneity.

Authors:  L Schnipper
Journal:  N Engl J Med       Date:  1986-05-29       Impact factor: 91.245

4.  [Cause of death in cancer patients].

Authors:  H Berger; N Freudenberg
Journal:  Med Welt       Date:  1983-01-28

5.  Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality.

Authors:  R H Grimm; J D Neaton; W Ludwig
Journal:  JAMA       Date:  1985-10-11       Impact factor: 56.272

6.  Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography.

Authors:  J B Kostis; D Turkevich; J Sharp
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

7.  Thromboembolic risk of postsplenectomy thrombocytosis.

Authors:  M A Boxer; J Braun; L Ellman
Journal:  Arch Surg       Date:  1978-07

8.  Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma.

Authors:  B R Kressel; K P Ryan; A T Duong; J Berenberg; P S Schein
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

9.  The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.

Authors:  K A Bauer; R D Rosenberg
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

10.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

Authors:  D Lovett; B Kozan; M Hadam; K Resch; D Gemsa
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

View more
  1 in total

Review 1.  Fibrinolytic mechanisms in tumor growth and spreading.

Authors:  T Südhoff; W Schneider
Journal:  Clin Investig       Date:  1992-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.